Bernd Schmidt
Directeur Technique/Scientifique/R&D chez SENSORION
Postes actifs de Bernd Schmidt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SENSORION | Directeur Technique/Scientifique/R&D | 11/12/2023 | - |
Historique de carrière de Bernd Schmidt
Anciens postes connus de Bernd Schmidt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - | - |
Formation de Bernd Schmidt
| Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Statistiques
Internationale
| Allemagne | 2 |
| Royaume-Uni | 2 |
| France | 2 |
Opérationnelle
| Graduate Degree | 1 |
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SENSORION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Bernd Schmidt
- Expérience
